Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 1,130 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 1,130 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $40.23, for a total value of $45,459.90. Following the completion of the transaction, the executive vice president now directly owns 244,955 shares in the company, valued at approximately $9,854,539.65. The trade was a 0.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, December 11th, Andrew Polovin sold 51,504 shares of Tempus AI stock. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56.

Tempus AI Price Performance

Shares of TEM opened at $33.03 on Friday. The company’s fifty day moving average price is $51.96. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Kovitz Investment Group Partners LLC bought a new stake in shares of Tempus AI during the 3rd quarter worth about $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI in the third quarter valued at $2,726,000. Sigma Planning Corp acquired a new position in Tempus AI during the third quarter worth about $1,323,000. Finally, Dakota Wealth Management bought a new stake in Tempus AI in the third quarter worth about $1,185,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TEM. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Guggenheim began coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Loop Capital boosted their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.